The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤ 40 years of age)

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 529-534

  Goliasch, Georg ^a   Wiesbauer, Franz ^a   Grafl, Andreas ^a   Ponweiser, Elisabeth ^a   Blessberger, Hermann ^a   Tentzeris, Ioannis ^b   Wojta, Johann ^a   Schillinger, Martin ^a   Huber, Kurt ^b   Maurer, Gerald ^a   Mannhalter, Christine ^a   Sunder Plaßmann, Raute ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Epidemiology; Myocardial infarction; p22 PHOX (CYBA); Premature coronary artery disease; ROS

Indexed keywords

ACUTE HEART INFARCTION; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYBA GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTECTION;

ADULT; ALLELES; CATHETERIZATION; CORONARY ARTERY DISEASE; FEMALE; HOMOZYGOTE; HUMANS; MALE; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; NADPH OXIDASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; REGRESSION ANALYSIS;

EID: 79952522413     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-08-0529     Document Type: Article

References (24)

1. Fournier JA, Cabezon S, Cayuela A, et al. Long-term prognosis of patients having acute myocardial infarction when
2. Jalowiec DA, Hill JA. Myocardial infarction in the young and in women. Cardiovasc Clin 1989; 20: 197-206. (Pubitemid 19171268)
3. Wiesbauer F, Blessberger H, Azar D, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J 2009; 30: 1073-1079.
4. Wiesbauer F, Blessberger H, Goliasch G, et al. Elevated risk of myocardial infarction in very young immigrants from former Yugoslavia. Eur J Epidemiol 2009; 24: 691-696.
5. Soccio M, Toniato E, Evangelista V, et al. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest 2005; 35: 305-314. (Pubitemid 40675604)
6. San Jose G, Moreno MU, Olivan S, et al. Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 2004; 44: 163-169. (Pubitemid 39014233)
7. Zalba G, San Jose G, Beaumont FJ, et al. Polymorphisms and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ Res 2001; 88: 217-222. (Pubitemid 32147311)
8. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653. (Pubitemid 350182388)
9. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277-283. (Pubitemid 40966856)
10. Moreno MU, San Jose G, Orbe J, et al. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 2003; 542: 27-31. (Pubitemid 36555708)
11. Rothman K, Greenland S. Modern Epidemiology. 1998: 147-162.
12. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Soc 1995; 57: 289-300.
13. Inoue N, Kawashima S, Kanazawa K, et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998; 97: 135-137. (Pubitemid 28124668)
14. Dupont W. Power calculations for matched case-control studies. Biometrics 1988; 44: 1157-1168 (Pubitemid 19026046)
15. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-1747.
16. Cai H, Duarte N, Wilcken DE, et al. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest 1999; 29: 744-748. (Pubitemid 29425515)
17. Hayaishi-Okano R, Yamasaki Y, Kajimoto Y, et al. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 2003; 26: 458-463. (Pubitemid 36929073)
18. Gardemann A, Mages P, Katz N, et al. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999; 145: 315-323. (Pubitemid 29359140)
19. Li A, Prasad A, Mincemoyer R, et al. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet 1999; 86: 57-61. (Pubitemid 29387717)
20. Saha N, Sanghera DK, Kamboh MI. The p22 phox polymorphism C242T is not associated with CHD risk in Asian Indians and Chinese. Eur J Clin Invest 1999; 29: 999-1002.
21. Di Castelnuovo A, Soccio M, Iacoviello L, et al. The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis. Thromb Haemost 2008; 99: 594-601.
22. Zahler S, Kupatt C, Becker BF. Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF-alpha. FASEB J 2000; 14: 555-564. (Pubitemid 30143175)
23. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004; 61: 461-470. (Pubitemid 38210152)
24. Tang H, Hao Q, Rutherford SA, et al. Inactivation of SRC family tyrosine kinases by reactive oxygen species in vivo. J Biol Chem 2005; 280: 23918-23925. (Pubitemid 40884880)